Marker Therapeutics (MRKR) Enterprise Value (2016 - 2025)
Marker Therapeutics (MRKR) has disclosed Enterprise Value for 11 consecutive years, with -$17.0 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 11.2% to -$17.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.0 million through Dec 2025, up 11.2% year-over-year, with the annual reading at -$17.0 million for FY2025, 11.2% up from the prior year.
- Enterprise Value for Q4 2025 was -$17.0 million at Marker Therapeutics, up from -$18.9 million in the prior quarter.
- The five-year high for Enterprise Value was -$6.4 million in Q1 2023, with the low at -$64.5 million in Q1 2021.
- Average Enterprise Value over 5 years is -$23.2 million, with a median of -$17.8 million recorded in 2022.
- The sharpest move saw Enterprise Value surged 77.79% in 2023, then crashed 110.49% in 2025.
- Over 5 years, Enterprise Value stood at -$43.5 million in 2021, then soared by 72.91% to -$11.8 million in 2022, then fell by 28.26% to -$15.1 million in 2023, then fell by 27.01% to -$19.2 million in 2024, then increased by 11.2% to -$17.0 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$17.0 million, -$18.9 million, and -$11.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.